These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35301903)

  • 1. Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection.
    Bouchlarhem A; Es-Saad O; Haddar L; Lamzouri O; Elaidouni G; Mimouni H; Bkiyar H; Housni B
    J Int Med Res; 2022 Mar; 50(3):3000605221082875. PubMed ID: 35301903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 and chronic myeloid leukemia: a systematic review.
    Ali EA; Al-Sadi A; Al-Maharmeh Q; Subahi EA; Bellamkonda A; Kalavar M; Panigrahi K; Alshurafa A; Yassin MA
    Front Med (Lausanne); 2023; 10():1280271. PubMed ID: 38327268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
    Khiali S; Khani E; Entezari-Maleki T
    J Clin Pharmacol; 2020 Sep; 60(9):1131-1146. PubMed ID: 32557541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of COVID-19-induced refractory status epilepticus by tocilizumab.
    Kizilkilic EK; Unkun R; Uygunoglu U; Delil S; Ozkara C
    Eur J Neurol; 2022 Sep; 29(9):2861-2863. PubMed ID: 35678591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
    Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
    J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe COVID-19 infection in a patient with a blastic transformation of a chronic myeloid leukemia and severe treatment-induced immunosuppression: a case report.
    Mounir L; Mehdi S; Kawtar F; Akram M; Youness ET; Meryem T; Othmane JT; Imane E; Hanane E; Boubakar C; Marieme C; Mouna L; Asmaa H; Asmaa Q
    Pan Afr Med J; 2020; 37(Suppl 1):34. PubMed ID: 33456658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
    Innes AJ; Cook LB; Marks S; Bataillard E; Crossette-Thambiah C; Sivasubramaniam G; Apperley J; Milojkovic D
    Br J Haematol; 2020 Aug; 190(4):e198-e200. PubMed ID: 32593183
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab: From Rheumatic Diseases to COVID-19.
    Raiteri A; Piscaglia F; Granito A; Tovoli F
    Curr Pharm Des; 2021; 27(13):1597-1607. PubMed ID: 33719967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
    Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C
    Mult Scler Relat Disord; 2020 Nov; 46():102592. PubMed ID: 33296987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
    Antony SJ; Davis MA; Davis MG; Almaghlouth NK; Guevara R; Omar F; Del Rey F; Hassan A; Arian MU; Antony N; Prakash BV
    J Med Virol; 2021 Jan; 93(1):491-498. PubMed ID: 32644254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Covid-19 cytokine storm by tocilizumab.
    Boretti A; Banik B
    J Med Virol; 2022 Mar; 94(3):823-828. PubMed ID: 34617604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports.
    Abdullah S; Bashir N; Mahmood N
    J Med Case Rep; 2021 Aug; 15(1):426. PubMed ID: 34364393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
    Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
    Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
    Samaee H; Mohsenzadegan M; Ala S; Maroufi SS; Moradimajd P
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107018. PubMed ID: 33045577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.